dts

DTS is a selective and isoform-specific RSK1 kinase inhibitor. It also has broad cancer therapeutic potential.

DTS-108 is a prodrug of SN38 (a topoisomerase I inhibitor). It is a conjugate formed by linking SN38 to a human oligopeptide through an esterase-sensitive crosslinker. DTS-108 exhibits anticancer activity against colorectal cancer, lung cancer, and breast cancer.

DTS-201 sodium (CPI-0004Na) is a peptide prodrug of Doxorubicin. It contains a tetrapeptide segment that is hydrolyzed by endopeptidases in the tumor microenvironment to produce metabolites, which are then converted into active Doxorubicin upon cellular entry. DTS-201 has demonstrated antitumor efficacy in xenograft models of prostate, breast, and lung cancers.

DTSSP Crosslinker, a cleavable ADC linker, is utilized in the synthesis of antibody-drug conjugates (ADCs).

FTISADTSK acetate is a stable endogenous signature peptide sourced from Trastuzumab, which can be monitored using selected reaction monitoring (SRM)[1].

FTISADTSK is an endogenous stable signature peptide derived from Trastuzumab, accurately assessed using selected reaction monitoring (SRM).